Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR6828(B)] to Mannose Receptor - Low endotoxin, Azide free
  • Suitable for: WB, Flow Cyt, ICC/IF
  • Reacts with: Mouse, Human

Overview

  • Product name

    Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free
    See all Mannose Receptor primary antibodies

  • Description

    Rabbit monoclonal [EPR6828(B)] to Mannose Receptor - Low endotoxin, Azide free

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, Flow Cyt, ICC/IFmore details
    Unsuitable for: IHC-P or IP

  • Species reactivity

    Reacts with: Mouse, Human

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • WB: Human lung tissue; ICC/IF: MOLT-4 (human lymphoblastic leukemia cell line); Flow Cyt: MOLT-4 (human lymphoblastic leukemia cell line).

  • General notes

    ab209327 is a carrier-free antibody designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our Low endotoxin, azide-free formats have low endotoxin level (≤ 1 EU/ml, determined by the LAL assay) and are free from azide, to achieve consistent experimental results in functional assays.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Images

  • Immunocytochemistry/ Immunofluorescence - Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)
    Immunocytochemistry/ Immunofluorescence - Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)

    This ICC data was generated using the same anti-Mannose Receptor antibody clone [EPR6828(B)] in a different buffer formulation (cat# ab125028).

    Immunocytochemistry/Immunofluorescence analysis MOLT-4 (Human lymphoblastic leukemia) cells labeling Mannose Receptor with ab125028 at 1 μg/mL. Cells were fixed with 100% methanol. ab150081, an AlexaFluor®488 Goat anti-Rabbit at 1/1000 was used as the secondary antibody. Cells were counter-stained with ab195889 Anti-Alpha Tubulin antibody [DM1A] (1/250) - Microtubule Marker (Alexa Fluor® 594). Nuclei were counterstained with DAPI (blue).

    Confocal image showing membranous staining on MOLT-4 cell line.

  • Flow Cytometry - Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)
    Flow Cytometry - Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)

    Flow Cytometry analysis of Molt-4 (human acute lymphoblastic leukemia ) cells labeling Mannose Receptor with unpurified ab125028 at 1/200 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488)(1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab125028).

  • OI-RD Scanning - Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)
    OI-RD Scanning - Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)
    Equilibrium disassociation constant (KD)
    Learn more about KD

    Click here to learn more about KD

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab125028).

  • Western blot - Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)
    Western blot - Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)
    All lanes : Anti-Mannose Receptor antibody [EPR6828(B)] (ab125028) at 1/1000 dilution

    Lane 1 : Human lung tissue lysate
    Lane 2 : Human brain tissue lysate
    Lane 3 : Mouse brain tissue lysate
    Lane 4 : U-937 (Human histiocytic lymphoma monocyte) whole cell lysate
    Lane 5 : THP-1 (Human monocytic leukemia monocyte) whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Predicted band size: 166 kDa
    Observed band size: 200 kDa
    why is the actual band size different from the predicted?
    Additional bands at: 160 kDa (possible non-specific binding), 65 kDa (possible non-specific binding)


    Exposure time: 20 seconds


    Blocking/Diluting buffer and concentration: 5% NFDM/TBST.

    The expression profile observed in U-937 and THP-1 is consistent with the literature (PMID: 20801507 and PMID: 30591689). Rabbit monoclonal [EPR16891] to GAPDH (ab181602) used as loading control.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab125028).

  • Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)
    Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-Mannose Receptor antibody [EPR6828(B)] - Low endotoxin, Azide free (ab209327)

© 2021 Astana Biomed Group LLP. All rights reserved.